vs
Encompass Health Corp（EHC）とFMC CORP（FMC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Encompass Health Corpの直近四半期売上が大きい（$1.5B vs $1.1B、FMC CORPの約1.4倍）。Encompass Health Corpの純利益率が高く（9.5% vs -158.8%、差は168.3%）。Encompass Health Corpの前年同期比売上増加率が高い（9.9% vs -11.5%）。FMC CORPの直近四半期フリーキャッシュフローが多い（$631.1M vs $116.7M）。過去8四半期でFMC CORPの売上複合成長率が高い（8.6% vs 8.3%）
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
FMCコーポレーションはペンシルベニア州フィラデルフィアに本社を置く米国の化学製品製造企業です。1883年に殺虫剤メーカーとして創業した後、事業を多角化し、第二次世界大戦中は米国陸軍省向けに水陸両用装軌式上陸車両の設計・製造を請け負いました。現在では世界中に7,000人の従業員を擁しています。
EHC vs FMC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.5B | $1.1B |
| 純利益 | $146.1M | $-1.7B |
| 粗利率 | — | 39.8% |
| 営業利益率 | 16.7% | -130.8% |
| 純利益率 | 9.5% | -158.8% |
| 売上前年比 | 9.9% | -11.5% |
| 純利益前年比 | 20.8% | -10457.1% |
| EPS（希薄化後） | $1.43 | $-13.77 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.5B | $542.2M | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.5B | $791.4M | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.3B | $1.0B | ||
| Q1 24 | $1.3B | $918.0M |
| Q4 25 | $146.1M | $-1.7B | ||
| Q3 25 | $126.5M | $-569.3M | ||
| Q2 25 | $142.1M | $66.7M | ||
| Q1 25 | $151.5M | $-15.5M | ||
| Q4 24 | $120.9M | $-16.3M | ||
| Q3 24 | $108.2M | $65.0M | ||
| Q2 24 | $114.1M | $295.1M | ||
| Q1 24 | $112.5M | $-2.7M |
| Q4 25 | — | 39.8% | ||
| Q3 25 | — | 23.8% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 40.0% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 36.3% | ||
| Q2 24 | — | 38.3% | ||
| Q1 24 | — | 37.0% |
| Q4 25 | 16.7% | -130.8% | ||
| Q3 25 | 14.9% | -73.1% | ||
| Q2 25 | 16.2% | 12.0% | ||
| Q1 25 | 16.4% | 7.4% | ||
| Q4 24 | 14.3% | 19.2% | ||
| Q3 24 | 13.6% | 12.7% | ||
| Q2 24 | 14.3% | 6.0% | ||
| Q1 24 | 13.6% | 8.1% |
| Q4 25 | 9.5% | -158.8% | ||
| Q3 25 | 8.6% | -105.0% | ||
| Q2 25 | 9.7% | 6.3% | ||
| Q1 25 | 10.4% | -2.0% | ||
| Q4 24 | 8.6% | -1.3% | ||
| Q3 24 | 8.0% | 6.1% | ||
| Q2 24 | 8.8% | 28.4% | ||
| Q1 24 | 8.5% | -0.3% |
| Q4 25 | $1.43 | $-13.77 | ||
| Q3 25 | $1.24 | $-4.52 | ||
| Q2 25 | $1.39 | $0.53 | ||
| Q1 25 | $1.48 | $-0.12 | ||
| Q4 24 | $1.18 | $-0.13 | ||
| Q3 24 | $1.06 | $0.52 | ||
| Q2 24 | $1.12 | $2.35 | ||
| Q1 24 | $1.10 | $-0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $72.2M | $584.5M |
| 総負債低いほど良い | $2.4B | $3.4B |
| 株主資本純資産 | $2.4B | $2.1B |
| 総資産 | $7.1B | $9.7B |
| 負債/資本比率低いほどレバレッジが低い | 1.00× | 1.62× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $72.2M | $584.5M | ||
| Q3 25 | $48.7M | $497.7M | ||
| Q2 25 | $99.1M | $438.2M | ||
| Q1 25 | $95.8M | $315.3M | ||
| Q4 24 | $85.4M | $357.3M | ||
| Q3 24 | $147.8M | $416.7M | ||
| Q2 24 | $154.4M | $471.5M | ||
| Q1 24 | $134.4M | $417.8M |
| Q4 25 | $2.4B | $3.4B | ||
| Q3 25 | $2.4B | $3.4B | ||
| Q2 25 | $2.3B | $3.4B | ||
| Q1 25 | $2.3B | $3.1B | ||
| Q4 24 | $2.4B | $3.1B | ||
| Q3 24 | $2.3B | $3.1B | ||
| Q2 24 | $2.7B | $3.1B | ||
| Q1 24 | $2.7B | $3.1B |
| Q4 25 | $2.4B | $2.1B | ||
| Q3 25 | $2.4B | $3.8B | ||
| Q2 25 | $2.3B | $4.4B | ||
| Q1 25 | $2.2B | $4.4B | ||
| Q4 24 | $2.1B | $4.5B | ||
| Q3 24 | $2.0B | $4.6B | ||
| Q2 24 | $1.8B | $4.6B | ||
| Q1 24 | $1.7B | $4.3B |
| Q4 25 | $7.1B | $9.7B | ||
| Q3 25 | $6.9B | $12.1B | ||
| Q2 25 | $6.8B | $12.3B | ||
| Q1 25 | $6.6B | $11.8B | ||
| Q4 24 | $6.5B | $11.7B | ||
| Q3 24 | $6.5B | $12.2B | ||
| Q2 24 | $6.4B | $12.1B | ||
| Q1 24 | $6.2B | $12.0B |
| Q4 25 | 1.00× | 1.62× | ||
| Q3 25 | 1.01× | 0.89× | ||
| Q2 25 | 1.02× | 0.76× | ||
| Q1 25 | 1.08× | 0.71× | ||
| Q4 24 | 1.14× | 0.69× | ||
| Q3 24 | 1.20× | 0.68× | ||
| Q2 24 | 1.46× | 0.68× | ||
| Q1 24 | 1.54× | 0.72× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $346.0M | $657.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $116.7M | $631.1M |
| FCFマージンFCF / 売上 | 7.6% | 58.3% |
| 設備投資強度設備投資 / 売上 | 14.8% | 2.4% |
| キャッシュ転換率営業CF / 純利益 | 2.37× | — |
| 直近12ヶ月FCF直近4四半期 | $439.2M | $-102.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $346.0M | $657.1M | ||
| Q3 25 | $270.8M | $-184.2M | ||
| Q2 25 | $270.2M | $65.9M | ||
| Q1 25 | $288.6M | $-545.0M | ||
| Q4 24 | $278.8M | $427.9M | ||
| Q3 24 | $267.8M | $159.5M | ||
| Q2 24 | $217.4M | $292.2M | ||
| Q1 24 | $238.8M | $-142.9M |
| Q4 25 | $116.7M | $631.1M | ||
| Q3 25 | $83.7M | $-207.9M | ||
| Q2 25 | $113.3M | $50.9M | ||
| Q1 25 | $125.5M | $-576.6M | ||
| Q4 24 | $80.1M | $406.3M | ||
| Q3 24 | $120.3M | $143.8M | ||
| Q2 24 | $60.5M | $282.3M | ||
| Q1 24 | $99.4M | $-163.6M |
| Q4 25 | 7.6% | 58.3% | ||
| Q3 25 | 5.7% | -38.3% | ||
| Q2 25 | 7.8% | 4.8% | ||
| Q1 25 | 8.6% | -72.9% | ||
| Q4 24 | 5.7% | 33.2% | ||
| Q3 24 | 8.9% | 13.5% | ||
| Q2 24 | 4.6% | 27.2% | ||
| Q1 24 | 7.6% | -17.8% |
| Q4 25 | 14.8% | 2.4% | ||
| Q3 25 | 12.7% | 4.4% | ||
| Q2 25 | 10.8% | 1.4% | ||
| Q1 25 | 11.2% | 4.0% | ||
| Q4 24 | 14.1% | 1.8% | ||
| Q3 24 | 10.9% | 1.5% | ||
| Q2 24 | 12.1% | 1.0% | ||
| Q1 24 | 10.6% | 2.3% |
| Q4 25 | 2.37× | — | ||
| Q3 25 | 2.14× | — | ||
| Q2 25 | 1.90× | 0.99× | ||
| Q1 25 | 1.90× | — | ||
| Q4 24 | 2.31× | — | ||
| Q3 24 | 2.48× | 2.45× | ||
| Q2 24 | 1.91× | 0.99× | ||
| Q1 24 | 2.12× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
FMC
| Insecticides | $440.3M | 41% |
| Herbicides | $378.8M | 35% |
| Fungicides | $140.4M | 13% |
| Plant Health | $65.6M | 6% |
| Other | $45.0M | 4% |
